Dev Prasad
Analyst
Lucid Capital Markets
Equibles does not estimate personal net worth.
About Dev Prasad
Dev Prasad is recorded as Analyst at Lucid Capital Markets. Dev Prasad has spoken on 2 earnings calls and 5 other investor events across 4 companies, most recently for Cue Biopharma, Inc. on September 21, 2026. Those appearances were for Acumen Pharmaceuticals, Inc. (ABOS), Verrica Pharmaceuticals Inc. (VRCA), aTYR PHARMA INC (ATYR) and Cue Biopharma, Inc. (CUE). The companies whose calls Dev Prasad spoke on are classified in the Healthcare sector.
Dev Prasad on recent calls
“One is if we look at week 12, the 4 and 2 mg per kilogram dose are nearly identical at 54% and 53% for HSS7, but they're substantially different at B28, at 60% and 31%.”
“And one is the slide 10 frame that phase three is partner enabled. So, is this a base case rather than self-funding? And another is on sub-Q. How are you thinking about the role of sub-Q in late-stage development?”
“And one is the slide 10 frame that phase three is partner enabled. So, is this a base case rather than self-funding? And another is on sub-Q. How are you thinking about the role of sub-Q in late-stage development?”
“One is, so we see unit growth continues to outpace net product revenue growth. How should we think about revenue conversion from a dispensed applicator over the next few quarters?”
“One following up to the last one, I'm not sure if you answered it or not, but are you seeing why can't growth primarily from new prescriber entering this launch curve or from higher utilization from existing high volume account?”
Affiliation history
-
Lucid Capital Markets
Analyst
Source not stated
Current
Company network
aTYR PHARMA INC
ATYR
Biotechnology · Healthcare
2 appearances
Latest appearance 2026-05-11
View calls and events